Prostate cancer is the most common cancer in men, with 1 in 8 diagnosed at some point in their lives.1 Indeed, with Men’s Health Awareness Month underway, the importance of tackling this prevalent diseas
Tue, 27/11/2018 - 08:30
Fri, 15/06/2018 - 08:30
London, UK, 15th June 2018 / Sciad Newswire / Check4Cancer is delighted to announce it has been awarded ‘Diagnostics p
Wed, 06/12/2017 - 08:00
Cambridge, UK, 6th December 2017 / Sciad Newswire / Domainex Ltd, a privately-owned drug discovery services company, is p
Thu, 26/10/2017 - 07:30
London, UK, 26th October 2017 / Sciad Newswire / This year’s Pharma Integrates conference in London, 15th-16th Nove
Tue, 26/09/2017 - 00:15
New approach informed by government priorities, consultancy with industry and the NHS, and a century of expertise
Thu, 29/06/2017 - 07:30
Australian immuno-oncology company Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of MiltuximabTM, a chimeric version of Minomic’s MIL-38 anti-Glypican1 antibody conjugated to the radioactive isotope 67Gallium.
Fri, 30/09/2016 - 10:12
ProAxsis Limited is pleased to announce that it has successfully registered a CE Mark for its novel ProteaseTag® Active Neutrophil Elastase Immunoassay.
Mon, 12/09/2016 - 11:15
London, UK, 12th September 2016 / Sciad Newswire / NALIA Systems is pleased to announce the filing of two new patent applications that highlight the co
Wed, 20/01/2016 - 13:00
BÜHLMANN Laboratories is proud to announce the availability of its products directly from its new North American affiliate, BUHLMANN Diagnostics Corp (BDC) in Southern New Hampshire.